胰高血糖素样肽-1受体激动剂使用与2型糖尿病患者全髋关节置换术后并发症增加无关
研究回顾性分析2016至2021年国家数据库中14,065例接受初次全髋关节置换术的2型糖尿病患者,经1:4倾向评分匹配比较使用与未使用GLP-1激动剂者的术后结局。结果显示未使用GLP-1激动剂者延长住院(≥3天)风险更高(OR 1.25,P=0.01),而使用GLP-1激动剂者90天手术或内科并发症、1年全因翻修、无菌性翻修及假体周围感染率均无显著差异。作者认为GLP-1激动剂与并发症风险增加无关,且与较低延长住院率相关,但需更多数据明确其在术前优化中的作用。
要点
- 未使用GLP-1激动剂者延长住院(≥3天)风险更高(OR 1.25,P=0.01)。
- 使用GLP-1激动剂者90天手术或内科并发症率无显著差异。
- 1年全因翻修、无菌性翻修及假体周围感染率无显著差异。
核心结论
- GLP-1激动剂与2型糖尿病全髋关节置换术后内科或手术并发症风险增加无关,且与较低延长住院率相关。
- 鉴于其潜在血糖控制和减重作用,需要更多数据明确GLP-1激动剂在术前优化中的作用以减少术后并发症。
研究设计与样本
- 回顾性队列研究(证据等级III级),使用国家数据库回顾2016至2021年14,065例接受初次全髋关节置换术的2型糖尿病患者。
- 采用1:4倾向评分匹配,将使用GLP-1激动剂者(n=812)与未使用者(n=3,248)匹配,匹配变量包括年龄、性别、胰岛素状态、其他降糖药使用、合并症和吸烟状态。
- 采用多因素logistic回归分析两组90天和1年全髋关节置换术结局。
主要发现
- 未使用GLP-1激动剂者延长住院(≥3天)发生率更高(OR 1.25,P=0.01)。
- 使用GLP-1激动剂者与未使用者相比,90天手术或内科并发症率无显著差异。
- 术后1年全因翻修、无菌性翻修或假体周围感染率无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glucagon-like peptide-1 (GLP-1) agonists have emerged as a powerful diabetic treatment adjunct; however, their effects on outcomes following total hip arthroplasty (THA) are not well known. This study aimed to compare the risk of complications in patients who had type 2 diabetes mellitus (DM) who were on GLP-1 agonists with those who were not on these medications. METHODS: In total, 14,065 patients who had type 2 DM undergoing primary THA between 2016 and 2021 were retrospectively reviewed using a national database. Propensity score matching was employed at a 1:4 ratio to match patients who used GLP-1 agonists (n = 812) to those who did not (n = 3,248). Patients were matched on age, sex, insulin status, presence of other diabetic medications, comorbidities, and smoking status. Multivariable logistic regressions were performed to examine 90-day and 1-year THA outcomes between groups. RESULTS: Patients who were not on GLP-1 agonists exhibited increased rates of extended hospital stays (≥3 days) (odds ratio 1.25, P = 0.01). Patients who were on GLP-1 agonists exhibited no significant differences in surgical or medical complication rates at 90 days compared to those not on GLP-1 agonists. There were also no significant differences in rates of all-cause revision THA, aseptic revision THA, or periprosthetic joint infection during the 1-year postoperative period. CONCLUSIONS: This study demonstrated that GLP-1 agonists were not associated with increased risks for medical or surgical complications in patients who had DM undergoing THA and were associated with lower rates of extended hospital stays after surgery. This study provides additional evidence regarding the association of GLP-1 agonist use before THA with postoperative outcomes. Given the potential for increased glycemic control and weight loss, more data are needed to delineate the role of GLP-1 agonists in the optimization of patients who have DM before THA to minimize postoperative complications. LEVEL OF EVIDENCE: Level III, retrospective cohort.
引用
- Heo KY, Goel RK, Woltemath A, et al. Glucagon-Like Peptide-1 Receptor Agonist Use Is Not Associated With Increased Complications After Total Hip Arthroplasty in Patients Who Have Type 2 Diabetes. J Arthroplasty. 2024. PMID: 39486470. doi:10.1016/j.arth.2024.10.099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。